title: Primary cryoablation for Gleason 8, 9, or 10 localized prostate cancer: Biochemical and local control outcomes from the Cryo OnLine database registry.
abstract: OBJECTIVE
  The increased use of cryoablation as an initial treatment for localized high-grade prostate cancer has been due to many factors including reports that cell kill from exposure to cryogenic temperatures is independent of cellular dedifferentiation and Gleason score. The objective of this study is to report the outcomes of primary cryoablation when used to treat Gleason 8, 9, or 10 localized prostate cancer at a large number of centers.
  
  
  METHODS
  Data from 1608 patients who underwent primary cryoablation at 27 centers were collected using the Cryo OnLine Database (COLD) registry. This analysis considers only the 77 patients who had a Gleason score of at least 8 and a minimum of 24 months of follow-up. Biochemical failure was defined according to both the original ASTRO definition (three rises) and the 2006 updated ASTRO (Phoenix) definition of nadir + 2. Biopsy was performed at the physician's discretion, but most commonly if a patient had a rising or suspicious prostate specific antigen (PSA).
  
  
  RESULTS
  The average age at treatment was 69.6 +/- 8.2 years. Pretreatment PSA was 16.2 +/- 17.9 ng/ml and the average Gleason was 8.5 +/- 0.6. Patients were followed for 39.0 +/- 18.8 months (range: 24-120 months) and 5-year follow-up was available for 12 patients. Eight-seven percent of the patients achieved a PSA nadir < 0.4 ng/ml. Five-year actuarial biochemical survivals was 64.4 +/- 6.0% and 44.6 +/- 8.0% for the ASTRO and Phoenix definitions, respectively. A total of 47 underwent posttreatment biopsy. Of these, 12 showed evidence of disease resulting in a positive biopsy rate for those who underwent biopsy of 25.5%. This yields a positive biopsy rate of the entire population of 15.6% (12/77).
  
  
  CONCLUSIONS
  Cryoablation, as a primary treatment for high-grade Gleason prostate cancer practiced over a wide spectrum of users provides definable biochemical and local control for a hard to manage patient population with aggressive disease.
authors.affiliation: Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
authors.forename: J Stephen
authors.initials: JS
authors.lastname: Jones
authors.forename: John C
authors.initials: JC
authors.lastname: Rewcastle